ICON plc/$ICLR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ICON plc
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
- Ticker
- $ICLR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 40,250
- Headquarters
- Dublin, Ireland
- Website
- www.iconplc.com
ICON plc Metrics
BasicAdvanced
$15B
36.60
$5.59
1.18
-
Price and volume
Market cap
$15B
Beta
1.18
52-week high
$219.04
52-week low
$66.57
Average daily volume
1.1M
Financial strength
Current ratio
1.315
Quick ratio
1.273
Long term debt to equity
0.381
Total debt to equity
0.384
Interest coverage (TTM)
1.07%
Profitability
EBITDA (TTM)
486.648
Gross margin (TTM)
23.44%
Net profit margin (TTM)
5.26%
Operating margin (TTM)
2.72%
Effective tax rate (TTM)
15.40%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
0.85%
Return on equity (TTM)
4.69%
Valuation
Price to earnings (TTM)
36.596
Price to revenue (TTM)
1.907
Price to book
1.68
Price to tangible book (TTM)
-5.69
Price to free cash flow (TTM)
17.471
Free cash flow yield (TTM)
5.72%
Free cash flow per share (TTM)
11.719
Growth
Revenue change (TTM)
1.82%
Earnings per share change (TTM)
62.85%
3-year revenue growth (CAGR)
0.90%
10-year revenue growth (CAGR)
17.55%
3-year earnings per share growth (CAGR)
-3.47%
10-year earnings per share growth (CAGR)
2.28%
What the Analysts think about ICON plc
Analyst ratings (Buy, Hold, Sell) for ICON plc stock.
Analyst projections of the future price of ICON plc stock.
Bulls say / Bears say
Q3 net business wins reached a record $3.15 billion, with a 1.56x book-to-bill and backlog up 4.8% sequentially to $24.5 billion. That gives ICON a larger base of contracted work to convert into future revenue. (ICON plc)
ICON raised its 2026 revenue outlook to $8.1–8.2 billion, from the previous $7.85–8.15 billion range, and narrowed its adjusted EPS outlook to $10.35–10.65. The higher outlook reflects improved visibility and stronger commercial momentum. (ICON plc)
Adjusted EBITDA grew 3% sequentially and its margin widened 70 basis points to 16.6%; adjusted EPS also rose 3.9% from Q2. This suggests better business mix and cost control are beginning to support earnings recovery. (ICON plc)
Q3 revenue fell 2.9% year on year, adjusted EPS declined to $2.66 from $3.20, and adjusted EBITDA was down 13.1%. Strong bookings have therefore not yet translated into year-on-year financial growth. (ICON plc)
An audit investigation found improper revenue adjustments and material weaknesses in financial controls; ICON restated revenue down by $65.3 million for 2023 and $92.7 million for 2024. This raises concerns about reporting reliability and whether control improvements will prove effective. (ICON plc)
Pass-through activity is expected to make up about one-third of revenue and helped lift ICON’s 2026 sales outlook, but it can weigh on profitability and make reported revenue less predictable. This mix could dilute the value of strong fee-based bookings. (ICON plc, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
ICON plc Financial Performance
Revenues and expenses
ICON plc Earnings Performance
Company profitability
Upcoming events
No upcoming events
ICON plc News
AllArticlesVideos
Funds containing ICON plc
Fund name | Fund size | $ICLR weighting |
|---|---|---|
iShares World Equity High Income Active£WINC | $685M | 0.03% |
Invesco Dow Jones Islamic Global Developed Markets$IGDA | $1.1B | 0.03% |
iShares USD Corporate Bond€LQDA | $3.5B | 0.02% |
iShares USD Corporate Bond£LQDS | $3.5B | 0.02% |
L&G Global Equity£LGGG | $2B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.